Standard BioTools Inc. (NASDAQ:LAB) Director Buys $387,000.00 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L purchased 150,000 shares of the business’s stock in a transaction dated Wednesday, May 22nd. The stock was bought at an average cost of $2.58 per share, for a total transaction of $387,000.00. Following the purchase, the director now owns 45,975,821 shares in the company, valued at $118,617,618.18. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Monday, May 20th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was bought at an average cost of $2.58 per share, for a total transaction of $258,000.00.
• On Friday, May 17th, Casdin Partners Master Fund, L purchased 352,072 shares of Standard BioTools stock. The stock was bought at an average cost of $2.56 per share, for a total transaction of $901,304.32.
• On Wednesday, May 15th, Casdin Partners Master Fund, L purchased 500,000 shares of Standard BioTools stock. The stock was bought at an average cost of $2.57 per share, for a total transaction of $1,285,000.00.
• On Monday, March 4th, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was bought at an average cost of $2.57 per share, for a total transaction of $642,500.00.

Standard BioTools Stock Up 0.4 %

Shares of Standard BioTools stock opened at $2.59 on Thursday. Standard BioTools Inc. has a 12 month low of $1.57 and a 12 month high of $3.16. The stock’s fifty day simple moving average is $2.60 and its 200 day simple moving average is $2.41.

Standard BioTools (NASDAQ:LAB) last released its earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The firm had revenue of $28.19 million during the quarter, compared to analysts’ expectations of $28.00 million. Standard BioTools had a negative return on equity of 144.74% and a negative net margin of 70.98%. As a group, research analysts anticipate that Standard BioTools Inc. will post -0.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on LAB shares. TD Cowen started coverage on Standard BioTools in a research note on Tuesday, April 16th. They set a “buy” rating and a $3.50 price objective on the stock. Jefferies Financial Group started coverage on Standard BioTools in a research note on Thursday, April 4th. They set a “buy” rating and a $3.25 price objective on the stock.

Hedge Funds Weigh In On Standard BioTools

A number of large investors have recently added to or reduced their stakes in LAB. Jump Financial LLC bought a new position in Standard BioTools during the 3rd quarter worth about $94,000. Barclays PLC bought a new position in Standard BioTools during the 3rd quarter worth about $140,000. Citigroup Inc. bought a new position in Standard BioTools during the 3rd quarter worth about $550,000. Acadian Asset Management LLC bought a new position in Standard BioTools during the 3rd quarter worth about $50,000. Finally, EAM Investors LLC bought a new position in shares of Standard BioTools in the 3rd quarter valued at about $1,375,000. Institutional investors own 53.74% of the company’s stock.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.